| Name | Title | Contact Details |
|---|
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN
The American Samoa Senate is the upper house of the American Samoa Fono.
McIntyre Youngblood Recruiting is a New Orleans, LA-based company in the Business Services sector.
All Pro Displays and Graphics is a Chino Hills, CA-based company in the Business Services sector.
Digital Infuzion is an SEI CMMI level 3-appraised, SBA-certified 8(a) and Small Disadvantaged information technology firm that offers innovative computer services, informatics, and enterprise solutions to research centers and healthcare organizations